Gilberto de Castro Junior
Gilberto de Castro Junior
Médico Assistente Doutor, Serviço de Oncologia Clínica, Instituto do Câncer do Estado de São Paulo
E-mail confirmado em lim24.fm.usp.br
Título
Citado por
Citado por
Ano
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia, JY Han, J Molina, ...
The Lancet 387 (10027), 1540-1550, 2016
36832016
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
E De Azambuja, F Cardoso, G de Castro, M Colozza, MS Mano, ...
British journal of cancer 96 (10), 1504-1513, 2007
9482007
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
5672017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
D Cameron, MJ Piccart-Gebhart, RD Gelber, M Procter, A Goldhirsch, ...
The Lancet 389 (10075), 1195-1205, 2017
4112017
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ...
The Lancet 393 (10167), 156-167, 2019
3232019
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum …
JPH Machiels, RI Haddad, J Fayette, LF Licitra, M Tahara, JB Vermorken, ...
The Lancet Oncology 16 (5), 583-594, 2015
314*2015
Side effects of approved molecular targeted therapies in solid cancers
C Widakowich, G de Castro Jr, E De Azambuja, P Dinh, A Awada
The oncologist 12 (12), 1443-1455, 2007
3092007
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised …
B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro Jr, ...
The Lancet 394 (10212), 1915-1928, 2019
2072019
Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation
P Lothaire, E de Azambuja, D Dequanter, Y Lalami, C Sotiriou, G Andry, ...
Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2006
1982006
Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
K Cocks, MT King, G Velikova, G de Castro Jr, MM St-James, PM Fayers, ...
European journal of cancer 48 (11), 1713-1721, 2012
1902012
Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS)≥ 1%: open-label …
G Lopes, YL Wu, I Kudaba, D Kowalski, BC Cho, G Castro, ...
Journal of Clinical Oncology 36 (18_suppl), LBA4-LBA4, 2018
1822018
Regenerative potential of leucocyte‐and platelet‐rich fibrin. Part A: intra‐bony defects, furcation defects and periodontal plastic surgery. A systematic review and meta‐analysis
AB Castro, N Meschi, A Temmerman, N Pinto, P Lambrechts, W Teughels, ...
Journal of clinical periodontology 44 (1), 67-82, 2017
1262017
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised …
L Paz-Ares, J Mezger, TE Ciuleanu, JR Fischer, J von Pawel, M Provencio, ...
The Lancet Oncology 16 (3), 328-337, 2015
1102015
Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the “do ut des” paradigm)
G de Castro Junior, F Puglisi, E de Azambuja, NS El Saghir, A Awada
Critical reviews in oncology/hematology 59 (1), 40-50, 2006
1102006
Regenerative potential of leucocyte‐and platelet‐rich fibrin. Part B: sinus floor elevation, alveolar ridge preservation and implant therapy. A systematic review
AB Castro, N Meschi, A Temmerman, N Pinto, P Lambrechts, W Teughels, ...
Journal of clinical periodontology 44 (2), 225-234, 2017
1052017
LBA8_PR KEYNOTE-048: phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G De Castro Jr, ...
Annals of Oncology 29 (suppl_8), mdy424. 045, 2018
1012018
The use of leucocyte and platelet‐rich fibrin in socket management and ridge preservation: a split‐mouth, randomized, controlled clinical trial
A Temmerman, J Vandessel, A Castro, R Jacobs, W Teughels, N Pinto, ...
Journal of clinical periodontology 43 (11), 990-999, 2016
902016
Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study
AG de Lima, RC Villar, G de Castro Jr, R Antequera, E Gil, ...
International Journal of Radiation Oncology* Biology* Physics 82 (1), 270-275, 2012
902012
Meta-analysis of first-line therapies in advanced non–small-cell lung cancer harboring EGFR-activating mutations
B Haaland, P San Tan, G de Castro Jr, G Lopes
Journal of Thoracic Oncology 9 (6), 805-811, 2014
872014
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell …
D Rischin, KJ Harrington, R Greil, D Soulieres, M Tahara, G de Castro, ...
Journal of Clinical Oncology 37 (15_suppl), 6000-6000, 2019
782019
O sistema não pode executar a operação agora. Tente novamente mais tarde.
Artigos 1–20